Skip to main content
EJNMMI Radiopharmacy and Chemistry

Table 4 Absorbed dose per administered activity for [225Ac]Ac-DOTA-JR11 and [177Lu]Lu-DOTA-JR11

From: First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

Target organ (rt)

d(rt) [mGy/kBq [225Ac]Ac-DOTA-JR11]

d(rt) [mGy/MBq [177Lu]Lu-DOTA-JR11]

Intestines

40.3

23.4

Stomach Wall

137.2

48.8

Heart

11.2

1.9

Kidneys

952.6

406.9

Liver

271.4

38.5

Lungs

37.2

37.7

Pancreas

284.4

120.8

Skeleton

0.1

2.8

Spleen

76.4

8.4

Total Body

44.0

12.6

Tumor (150 mg)

328.5

464.4

T/K ratioa

0.35

1.14

  1. The alpha-contribution to the absorbed dose by [225Ac]Ac-DOTA-JR11 were weighted with an RBE = 5. The last row indicates the tumor/kidney absorbed dose ratio
  2. aTumor-to-kidney ratio
Back to article page